FDA clears soft mist inhaler trial for lung disease
United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD. Four times a day, one breath each time. That’s the dosing routine United Therapeutics plans for treprostinil SMI, a handheld soft-mist inhaler that the company is now cleared to test in pe
<p>United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD. Four times a day, one breath each time. That’s the dosing routine United Therapeutics plans for treprostinil SMI, a handheld soft-mist inhaler that the company is now cleared to test in pe</p>